Molecular and Clinical Sciences Research Institute, St George's University of London, Cardiovascular Clinical Academic Group, St George's University Hospitals National Health Service (NHS) Foundation Trust, United Kingdom (Y.D.W., V.B., M.M., H.R., M.P., S.S., E.R.B.).
European Reference Network for Rare & Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart) (Y.D.W., Y.M., V.B., J.B., L.C., R.T., M.M., H.R., J.-J.S., J.-B.G., D.S.-M., E.A.N., R.R., M.P., F.K., F.D., S.C., M.T., A.A.M.W., S.S., P.J.S., V.P., C.R.B., E.R.B.).
Circ Genom Precis Med. 2020 Dec;13(6):e002911. doi: 10.1161/CIRCGEN.120.002911. Epub 2020 Nov 9.
Brugada syndrome (BrS) is characterized by the type 1 Brugada ECG pattern. Pathogenic rare variants in (mutations) are identified in 20% of BrS families in whom incomplete penetrance and genotype-negative phenotype-positive individuals are observed. E1784K- is the most common mutation identified. We determined the association of a BrS genetic risk score (BrS-GRS) and mutation type on BrS phenotype in BrS families with mutations.
Subjects with a spontaneous type 1 pattern or positive/negative drug challenge from cohorts harboring mutations were recruited from 16 centers (n=312). Single nucleotide polymorphisms previously associated with BrS at genome-wide significance were studied in both cohorts: rs11708996, rs10428132, and rs9388451. An additive linear genetic model for the BrS-GRS was assumed (6 single nucleotide polymorphism risk alleles).
In the total population (n=312), BrS-GRS ≥4 risk alleles yielded an odds ratio of 4.15 for BrS phenotype ([95% CI, 1.45-11.85]; =0.0078). Among -positive individuals (n=258), BrS-GRS ≥4 risk alleles yielded an odds ratio of 2.35 ([95% CI, 0.89-6.22]; =0.0846). In -negative relatives (n=54), BrS-GRS ≥4 alleles yielded an odds ratio of 22.29 ([95% CI, 1.84-269.30]; =0.0146). Among E1784K- positive family members (n=79), hosting ≥4 risk alleles gave an odds ratio=5.12 ([95% CI, 1.93-13.62]; =0.0011).
Common genetic variation is associated with variable expressivity of BrS phenotype in families, explaining in part incomplete penetrance and genotype-negative phenotype-positive individuals. mutation genotype and a BrS-GRS associate with BrS phenotype, but the strength of association varies according to presence of a mutation and severity of loss of function.
Brugada 综合征(BrS)的特征是 1 型 Brugada 心电图模式。在不完全外显和基因型阴性表型阳性个体中观察到的 BrS 家族中,确定了致病性罕见变异(突变)占 20%。E1784K-是最常见的突变。我们确定了 BrS 遗传风险评分(BrS-GRS)和突变类型与携带突变的 BrS 家族的 BrS 表型的关联。
从携带突变的队列中招募具有自发性 1 型模式或阳性/阴性药物挑战的受试者(n=312)。在两个队列中研究了先前与全基因组显著相关的 BrS 的单核苷酸多态性:rs11708996、rs10428132 和 rs9388451。假设了 BrS-GRS 的加性线性遗传模型(6 个单核苷酸多态性风险等位基因)。
在总人群(n=312)中,BrS-GRS≥4 个风险等位基因使 BrS 表型的比值比为 4.15([95%置信区间,1.45-11.85];=0.0078)。在 -阳性个体(n=258)中,BrS-GRS≥4 个风险等位基因使比值比为 2.35([95%置信区间,0.89-6.22];=0.0846)。在 -阴性亲属(n=54)中,BrS-GRS≥4 个等位基因使比值比为 22.29([95%置信区间,1.84-269.30];=0.0146)。在 E1784K-阳性家族成员(n=79)中,携带≥4 个风险等位基因的比值比为 5.12([95%置信区间,1.93-13.62];=0.0011)。
常见遗传变异与携带突变的家族中 BrS 表型的可变表达相关,部分解释了不完全外显和基因型阴性表型阳性个体。突变基因型和 BrS-GRS 与 BrS 表型相关,但关联的强度取决于突变的存在和功能丧失的严重程度。